The CONQUER study was double-blind, placebo-controlled clinical trial that examined the potential benefits of the combination product Qsymia (phenterimine and topiramate) in patients who were overweight and obese. Our moderator and panelists explore the findings of this study and how this new information should be applied to practice.
It’s been six months since your patient started treatment for an unprovoked venous clot. Everything has gone well and you’ve both been planning for this day when warfarin therapy can be stopped. Now what?
The PrimoTinA - asthma studies are two replicate double-blind clinical trials examining the benefits of adding inhaled tiotropium to standard asthma therapies in patients who have not achieved optimal control. Our moderator and panelists explore the findings of this study and how this new information should be applied to practice.
JNC7, now more than a decade old, recommends β-blockers as second line therapy in patients without compelling indications, after a thiazide diuretic, on equal footing with angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, and calcium channel blockers.1 Should this class still play a role in the treatment of hypertension in patients without compelling indications?
Does insulin worsen cardiovascular outcomes and cause cancer? Should insulin be reserved as the last resort?
The biggest superstar in the dietary supplement industry is fish oil. It is available over-the-counter and you can even buy orange juice fortified with it. Unfortunately, most of these products contain very low amounts of omega-3 fatty acids (O3FA).
The Patient Protection and Affordable Care Act (PPACA but often called the ACA) was signed into law by President Barack Obama on March 23, 2010 after it passed both the House and Senate following 2 years of debate in Congress. On June 28, 2012, the US Supreme Court upheld the constitutionality of many of the most controversial provisions of the law – including the so-called “individual mandate” to purchase health insurance.
In March 2012, the FDA sought feedback on a proposal to expand the scope of OTC drugs to include a class of medications that could be dispensed by a pharmacist without a prescription, under the conditions of "safe use". According to the proposal, conditions of safe use could include an intervention by a pharmacist to select medications from this category of nonprescription drugs for the treatment or management of specific disease states (e.g., dyslipidemia, asthma).